DERBY-BURTON LOCAL CANCER NETWORK FILENAME ESHAP.DOC CONTROLLED DOC NO: HCCPG B44. ESHAP Regimen

Similar documents
Gemcitabine, Dexamethasone and Cisplatin GDP Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen

Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen

High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma

DERBY-BURTON LOCAL CANCER NETWORK FILENAME CEOP.DOC CONTROLLED DOC NO: HCCPG B21 CSIS Regimen Name: CEOP. CEOP Regimen

Rituximab-CHOP Regimen - ENRICH Study

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-GCVP.DOC CONTROLLED DOC NO: HCCPG B12 CSIS Regimen Name: R-GCVP. R-GCVP Regimen

R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)

Nordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC)

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M

R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma

FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1)

Gemcitabine + Cisplatin Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy

Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study

Gemcitabine & Cisplatin

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

E 90 C followed by Weekly Paclitaxel

SUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in

Weekly Cisplatin + Radiotherapy - Interlace study -

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case

Burkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.

IBRUTINIB + Rituximab, Treatment Period - ENRICH Study

Bevacizumab + Paclitaxel + Cisplatin

5-FU & Cisplatin + Cetuximab

X M/ (R) Dose adjusted (DA)-EPOCH-R

Cisplatin Doxorubicin Sarcoma

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)

Subcutaneous Rituximab with or without Ibrutinib, Maintenance Period - ENRICH Study

(R) CODOX M / (R) IVAC

CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated

DA-EPOCH-R (Etoposide/Inpatient)

(High dose METHOTREXATE, high dose CYTARABINE, RITUXIMAB and THIOTEPA)

BEAM. Lymphoma group OxBMT SCHEDULE SUMMARY. Date:

1 Acute Lymphoblastic Leukaemia

DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:

Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy

This is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21

VIP (Etoposide, Ifosfamide and Cisplatin)

Gemcitabine + Capecitabine (ESPAC-4 Trial)

DTPACE. Myeloma group INDICATION

TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour

(primary CNS lymphoma)

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

NECN CHEMOTHERAPY HANDBOOK PROTOCOL

ALL Phase 2 Induction (25-60 years)

CISPLATIN Chemo-radiation regimen Gynaecological Cancer

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix

TIP Paclitaxel, Ifosfamide and Cisplatin

Breast Pathway Group EC x 4: Epirubicin & Cyclophosphamide in Early Breast Cancer

NB. This version combines both previous inpatient and ambulatory protocols. See DRUG REGIMEN section for details.

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer

SMILE (Etoposide, Ifosfamide, Methotrexate and Dexamethasone)

(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.

PVACE-BOP (Hodgkin s Lymphoma)

Vincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma

Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors:

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane

Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck

ECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic

Paclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen

Cisplatin and Pemetrexed (NSCLC, mesothelioma)

Docetaxel + Nintedanib

LYIVAC (Magrath B) + R (rituximab) [To be used after LYCODOX-M (Magrath A) + R]

EC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen

Carfilzomib and Dexamethasone (CarDex)

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer

StRs and CT doctors in haematology. September Folinic acid dose modified.

2.07 Protocol Name: CHOP & Rituximab

Standard care plan for Carboplatin and Etoposide Chemotherapy References

Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE:

ADULT Updated: September 4, 2018

Cisplatin / Paclitaxel Gynaecological Cancer

R-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative

Doxorubicin and Ifosfamide Sarcoma

Burkitt lymphoma, double hit lymphoma or high IPI diffuse large B-cell lymphoma.

Docetaxel + Carboplatin + Trastuzumab

Dasatinib (SPIRIT 2 Trial)

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Cisplatin and Fluorouracil

Note: There are other bendamustine protocols, ensure this is the correct one for a given patient.

1.28 Protocol Name: CODOX-M/IVAC

Network Chemotherapy Regimens

Cisplatin and Gemcitabine (bladder)

Guideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology

O-CVP with maintenance Obinutuzumab

BEACOPP-14/ Escalated BEACOPP

ALL MAINTENANCE (25-60 years)

Fludarabine-Cyclophosphamide plus Rituximab (FC-R) for Chronic Lymphocytic Leukaemia

Durvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study

Cisplatin and Fluorouracil (palliative)

Breast Pathway Group FEC75 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer

Oxaliplatin and Gemcitabine

R-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01

CAPECITABINE (METASTATIC BREAST CANCER) (BRWOS-002/1)

Transcription:

ESHAP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory lymphoma, multiple myeloma Treatment Intent Salvage or stem cell mobilisation (When IVE is contra-indicated or failure to mobilise with high dose Cyclophosphamide ) Anti-Emetics Pre-chemotherapy 3 (but no Dex premed) Post-chemotherapy C Frequency & Duration Every 21 days (or upon recovery of bone marrow) for 2 to 4 cycles Day 1 Urine output must be >100ml/hr before 6 0.9% 0.9% 1000ml Intravenous infusion over 2 (Via Line 1) 500ml Intravenous infusion over 30 (if urine output remains below 100 ml/hr) (Via Line 1) Ondansetron 8mg Oral or intravenous bolus as a (Via Line 1) filter over 24 (Via Line 1). 1000ml Intravenous infusion over 19 REVIEWED BY: K.Graham AUTHORISED BY: Dr J Addada PAGE 1 of 6

Aciclovir 400mg Oral twice daily for 21 days Omeprazole 20mg Oral once daily for 21 days Allopurinol 300mg Oral once daily for 1-2 cycles Cotrimoxazole 480mg Oral once daily for 21 days Fluconazole 100mg Oral once daily until neutrophils>1x10 9 /l Metoclopramide 10-20mg Oral four times daily for 4 days, then as required Day 2 Ondansetron 8mg Oral or intravenous bolus as a filter over 24 (Via Line 1) 6. 1000ml Intravenous infusion over 22 Day 3 Ondansetron 8mg Oral or intravenous bolus as a filter over 24 (Via Line 1) REVIEWED BY: K.Graham AUTHORISED BY: Dr J Addada PAGE 2 of 6

6. 1000ml Intravenous infusion over 22 Day 4 Ondansetron 8mg Oral or intravenous bolus as a filter over 24 (Via Line 1) 6. Prednisolone (Predsol 0.5%) 1000ml Intravenous infusion over 22 1 drop Eye drops 4 times daily in each eye for 7 days Day 5 Ondansetron 8mg Oral or intravenous bolus as a REVIEWED BY: K.Graham AUTHORISED BY: Dr J Addada PAGE 3 of 6

Cytarabine 2000mg/m 2 Intravenous infusion in 500ml sodium chloride 0.9% over 3 0.9% + 20 mmol 1000ml Intravenous infusion over 10 1000ml Intravenous infusion over 8 Day 6 Dexamethasone 4mg Oral twice daily for 2 days (Day 6) Stem cell mobilisation patients only G-CSF (Lenograstim ) 263 micrograms (BSA <1.8m 2 ) Or 368 micrograms (BSA >1.8m 2 ) Subcutaneous injection ONCE daily until adequate stem cell harvest Day 7 Filgrastim biosimilar 300micrograms Subcutaneous injection ONCE daily until neutrophils > 1x10 9 /l (supply 7 doses) Day 8 Dexamethasone 2mg Oral twice daily for 2 days Notes: For mobilising cycles of ESHAP, GCSF is commenced on day 6 and continued daily until adequate stem cells have been collected. Stem cells are harvested on day 15 provided the WCC exceeds 1 x 10 9 /l. Baseline investigations The 24 hour creatinine clearance prior to the first treatment should be > 40 ml/minute. Repeat 24 hour urine collections should be performed prior to each subsequent cycle to ensure a creatinine clearance of > 40 ml/minute. Dose modifications and toxicities 1. Haematological toxicity At the start of each cycle the neutrophil count should be > 1.0 x 10 9 /l and platelets > 100 x 10 9 /l unless cytopenias are considered to be disease-related. REVIEWED BY: K.Graham AUTHORISED BY: Dr J Addada PAGE 4 of 6

1. Renal impairment Cisplatin GFR ml/min Cisplatin Dose >60 100% 40-60 50% <40% Omit Cytarabine GFR ml/min Cytarabine Dose 60 100% 46-59 60% 31-45 50% 30 Omit Etoposide GFR ml/min Etoposide Dose >50 100% 15-50 75% <15 50% 2. Hepatic impairment Etoposide Bilirubin AST/ALT micromol/l IU/L Dose 26-51 60-180 50% >51 >180 omit Supportive care 1. Urine output should be maintained at > 100 ml/hour before (for at least 1 hour), during and chemotherapy (24 ). Accurate fluid balance must be kept. Mannitol 10% infusion is the preferred diuretic. If urine output remains <100ml/hr, a further dose of 100ml may be given by intravenous infusion over 10. Urine output should increase within 30 of commencing the infusion. If urine output remains <100ml/hr 30, a 10 mg stat IV bolus of furosemide may be given to increase urine output. If 30 the furosemide dose urine output has still not improved, the Consultant should be contacted for advice. 2. It is advisable to give allopurinol (300mg) once a day for the first 1 or 2 courses of therapy whilst there is bulky disease. Reduce dose to 100mg daily if GFR <10mls/min. REVIEWED BY: K.Graham AUTHORISED BY: Dr J Addada PAGE 5 of 6

3. All patients should receive Pneumocystis jirovecii prophylaxis throughout treatment: Co-trimoxazole 480mg ONCE daily. In cases of allergy to co-trimoxazole, consider dapsone 100mg daily. 4. Antifungal prophylaxis with Fluconazole 100mg daily until neutrophils >1x10 9 /l 5. Omeprazole 20mg once daily. 6. Aciclovir 400mg twice daily. References 1. Velasquez W.S. et al.; ESHAP An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study; J. Clin. Oncol.; 1994; 12 (6): 1169-1176 REVIEWED BY: K.Graham AUTHORISED BY: Dr J Addada PAGE 6 of 6